Immunotherapy of AML

1Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The applications of chemotherapy for the treatment of AML have been unchanged over the past three decades, with only 30% of patients demonstrating disease-free survival (DFS) [118]. Despite achieving CR following induction chemotherapy, the majority of patients relapse and succumb to their disease [6]. In view of the limitations encountered by cytarabine/anthracycline based regimes, attention has shifted to immunotherapy as a means to treat AML and provide significant long-term DFS. This chapter will discuss the role of the immune system and recent advances in immunotherapy for the treatment of AML, focusing on cellular and non-cellular approaches. © 2009 Springer Science+Business Media, LLC.

Cite

CITATION STYLE

APA

Alatrash, G., & Molldrem, J. J. (2010). Immunotherapy of AML. Cancer Treatment and Research. https://doi.org/10.1007/978-0-387-69259-3_14

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free